EUVIMEDEUVIMED entdecken
MetaanalyseNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis

Dosisabhängige protektive Effekte neuer Antidiabetika auf Delir, Depression, Demenz und Koma: Evidenz aus einer Netzwerk-Metaanalyse

Ping-Tao Tseng iD, Bing-Yan Zeng, Chih-Wei Hsu iD, Mein-Woei Suen, Chao-Ming Hung, Andre F Carvalho, Brendon Stubbs, Yen-Wen Chen, Tien-Yu Chen, Wei-Te Lei, Pao-Yen Lin, Jiann-Jy Chen und 5 weitere

Journal of the Royal Society of Medicine · 2026-02 · 119 (2) · 46-54

DOI: 10.1177/01410768251395877 ↗

Auf einen Blick

In 62 RCTs mit 200.068 Teilnehmenden wurden GLP-1-Rezeptoragonisten und SGLT2-Inhibitoren verglichen. Nur hochdosiertes Dapagliflozin senkte Delir und Depression signifikant.

Fragestellung

Unterscheiden sich GLP-1-Rezeptoragonisten und SGLT2-Inhibitoren hinsichtlich Delir, Depression, Demenz und Koma?

Methode

Frequenzistische Netzwerk-Metaanalyse von RCTs; Robustheitsprüfung mit Bayes-Framework. Eingeschlossen wurden Personen ohne kognitive oder psychiatrische Vorerkrankung.

Ergebnisse

62 RCTs mit 200.068 Teilnehmenden. Nur hochdosiertes Dapagliflozin (10 mg/Tag) reduzierte Delir und Depression signifikant, besonders bei Typ-2-Diabetes. Dulaglutid und Liraglutid waren mit kognitiver Verbesserung verbunden.

Schlussfolgerung der Autor:innen

Die Analyse zeigt agentenspezifische neuroprotektive Profile: SGLT2-Inhibitoren, besonders hochdosiertes Dapagliflozin, könnten Delir und Depression mindern; GLP-1-Rezeptoragonisten, vor allem Dulaglutid und Liraglutid, könnten die Kognition verbessern.

Kernaussagen

  • Nur hochdosiertes Dapagliflozin senkte Delir und Depression signifikant
  • Dulaglutid und Liraglutid waren mit kognitiver Verbesserung verbunden
  • Für Demenz und Koma zeigten sich keine signifikanten Vorteile

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of the Royal Society of Medicine, online erschienen am 08.12.2025. Verfasst von Ping-Tao Tseng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung 804, Taiwan. Hauptthemen laut MEDLINE: Dementia, Delirium, Hypoglycemic Agents, Coma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Emerging evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors may exert neuroprotective effects. However, the comparative efficacy of individual agents remains unclear. This network meta-analysis (NMA) aimed to evaluate the differential impacts of these therapies on the incidence of mental status changes, specifically delirium, depression, dementia and coma.

Design

A frequentist NMA was conducted using data from randomised controlled trials (RCTs) investigating GLP-1 receptor agonists or SGLT2 inhibitors. The robustness of the findings was verified through a Bayesian NMA framework.

Setting

This study adopted a confirmatory framework focusing on pre-defined neuropsychiatric adverse outcomes in alignment with Cochrane recommendations.

Participants

Included trials enrolled individuals without baseline cognitive or psychiatric disorders. Main outcome measures: The primary endpoint was the incidence of delirium, depression, dementia or coma during treatment. Secondary endpoints included changes in cognitive performance and drop-out rates.

Results

A total of 62 RCTs comprising 200,068 participants were included. Among all treatments, only high-dose dapagliflozin (10 mg/day) significantly reduced the occurrence of delirium and depression, particularly in patients with type 2 diabetes. Dulaglutide and liraglutide were the only agents associated with cognitive improvement. No significant benefits were observed for dementia or coma across all agents.

Conclusions

This analysis highlights agent-specific neuroprotective profiles: SGLT2 inhibitors, especially high-dose dapagliflozin, may mitigate the onset of delirium and depression, while GLP-1 receptor agonists, notably dulaglutide and liraglutide, may enhance cognitive function. These findings warrant consideration in selecting antihyperglycemic therapies for individuals at elevated neuropsychiatric risk.

Trial registration

PROSPERO CRD42024601021. The study protocol was approved by the Institutional Review Board of the Tri-Service General Hospital, National Defense Medical Center (TSGHIRB E202516007).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DementiaDeliriumHypoglycemic AgentsComaDepressionSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Neuroprotective AgentsHumansNetwork Meta-Analysis as TopicGlucagon-Like Peptide-1 Receptor AgonistsRandomized Controlled Trials as TopicDose-Response Relationship, Drug

Stichwörter der Autor:innen

GLP-1 receptor agonistNetwork meta-analysisSGLT2 inhibitordeliriumdepressionmental status

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsNeuroprotective Agents

Autor:innen und Institutionen

  • Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
  • Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
  • Department of Psychology, College of Medical and Health Science, Asia University, Taichung 413, Taiwan.
  • Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung 811, Taiwan.
  • Department of Internal Medicine, E-Da Dachang Hospital, I-Shou University, Kaohsiung 807, Taiwan.
  • Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.

ORCID-Profile: Ping-Tao Tseng, Chih-Wei Hsu, Kuan-Pin Su, Chih-Sung Liang

Zitieren

APA

Tseng, P. T., Zeng, B. Y., Hsu, C. W., Suen, M. W., Hung, C. M., Carvalho, A. F., Stubbs, B., Chen, Y. W., Chen, T. Y., Lei, W. T., Lin, P. Y., Chen, J. J., Su, K. P., Wang, H. Y., Zeng, B. S., Shiue, Y. L., & Liang, C. S. (2026). The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis. Journal of the Royal Society of Medicine, 119(2), 46-54. https://doi.org/10.1177/01410768251395877

Vancouver

Tseng PT, Zeng BY, Hsu CW, Suen MW, Hung CM, Carvalho AF, et al. The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis. Journal of the Royal Society of Medicine. 2026;119(2):46-54. doi:10.1177/01410768251395877

BibTeX
@article{Tseng2026,
  author = {Tseng, Ping-Tao and Zeng, Bing-Yan and Hsu, Chih-Wei and Suen, Mein-Woei and Hung, Chao-Ming and Carvalho, Andre F and Stubbs, Brendon and Chen, Yen-Wen and Chen, Tien-Yu and Lei, Wei-Te and Lin, Pao-Yen and Chen, Jiann-Jy and Su, Kuan-Pin and Wang, Hung-Yu and Zeng, Bing-Syuan and Shiue, Yow-Ling and Liang, Chih-Sung},
  title = {The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis},
  journal = {Journal of the Royal Society of Medicine},
  year = {2026},
  volume = {119},
  number = {2},
  pages = {46--54},
  doi = {10.1177/01410768251395877}
}
Kostenlos starten →